Details

Autor(en) / Beteiligte

• MARTINEZ, Fernando J
• DE ANDRADE, Joao A
• ANSTROM, Kevin J
• KING, Talmadge E
• RAGHU, Ganesh

Titel

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis

Ist Teil von

• The New England journal of medicine, 2014-05, Vol.370 (22), p.2093-2101

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Acetylcysteine, which has been advocated as a treatment for patients with idiopathic pulmonary fibrosis, showed no benefit over placebo with respect to loss of lung function in such patients at 60 weeks. Idiopathic pulmonary fibrosis is a chronic, progressive lung disease of unknown cause that is characterized by the histopathological or radiologic patterns of usual interstitial pneumonia in a typical clinical setting. 1 , 2 To date, no pharmacologic therapies have been shown to improve survival. 1 In the IFIGENIA study (Idiopathic Pulmonary Fibrosis International Group Exploring N -Acetylcysteine I Annual), investigators found that a three-drug regimen (prednisone, azathioprine, and acetylcysteine) preserved pulmonary function better than a two-drug regimen consisting of azathioprine plus prednisone. 3 In PANTHER-IPF (Prednisone, Azathioprine, and N -Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis), patients with mild-to-moderate impairment in . . .